Quick Answer
LianBio reported Stockholders Equity of $259.87 million for fiscal year 2022.
LianBio Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2022 | $259.87M | -26.5% |
| 2021 | $353.56M | +366.2% |
| 2020 | -$132.84M | -796.6% |
| 2019 | -$14.82M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $202.34M | -25.8% | -8.7% |
| June 30, 2023 | $221.73M | -24.2% | -7.9% |
| March 31, 2023 | $240.65M | -27.3% | -7.4% |
| December 31, 2022 | $259.87M | -26.5% | -4.7% |
| September 30, 2022 | $272.82M | +207.8% | -6.7% |
| June 30, 2022 | $292.42M | +218.2% | -11.7% |
| March 31, 2022 | $331.00M | +322.8% | -6.4% |
| December 31, 2021 | $353.56M | +460.5% | +239.7% |
- LianBio showed a decrease of -26.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2022 period, LianBio’s stockholders equity has grown by 1854.0% (from -$14.82 million to $259.87 million).
- The most recent figure is from LianBio’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 28, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: